InvestSMART

Imagion Biosystems Limited (ASX:IBX)

ALERT: Price-sensitive ASX Announcement for IBX
Current share price for IBX : $0.012 -0.003 (-20%)+
Announcement
Release
25 Jun 2026 9:28AM
Price at Release
$0.015
Full Release
download
Summary
Imagion Biosystems Limited has secured firm commitments for a capital raising of $3.75 million to fund the commencement of a Phase 1b/2 clinical trial for its MagSense® HER2 imaging agent across multiple sites in the USA. This funding follows the clearance of the company's IND application by the FDA, marking a significant technical and organizational milestone. The capital raising was led by CPS Capital Group Pty Ltd, and involves a two-tranche placement of new shares to sophisticated investors at a price of $0.012 per share, with free attaching listed options. The proceeds are intended to support the initiation of the clinical trial, manufacturing activities, intellectual property development, and collaborations for advancing the company's molecular MRI technology. The trial is expected to begin patient recruitment in Q3 2026.
Key Points
  • Imagion Biosystems secures $3.75 million for clinical trials.
  • Funding follows FDA clearance for IND application.
  • Capital raising led by CPS Capital Group Pty Ltd.
  • Two-tranche placement of shares at $0.012 each.
  • Proceeds to fund Phase 1b/2 trial of MagSense® HER2 imaging agent.
  • Trial to commence patient recruitment in Q3 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.